Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1708-1715

  Wang, Laurene H ^a   Chittick, Gregory E ^a   McDowell, James A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CD4 ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ZIDOVUDINE GLUCURONIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; NAUSEA; NECK; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; THORAX PAIN;

EID: 0032772952     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1708     Document Type: Article

References (30)

1. Angel, J. B., E. K. Hussey, S. T. Hall, K. H. Donn, D. M. Morris, J. P. McCormack, J. S. G. Montaner, and J. Ruedy. 1993. Pharmacokinetics of 3TC (GR 109714X) administered with and without food to HIV-infected patients. Drug Invest. 6:70-74.
2. Barry, M., J. L. Howe, S. Ormesher, D. J. Back, A. M. Breckenridge, C. Bergin, F. Mulcahy, N. Beeching, and F. Nye. 1994. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br. J. Clin. Pharmacol. 37:421-426.
3. Blum, M. R., S. H. T. Liao, S. S. Good, and P. De Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85 (Suppl. 2A):189-194.
4. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1997. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the Internatioral AIDS Society-USA Panel. JAMA 277:1962-1969.
5. Collins, J. M., and J. D. Unadkat. 1989. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin. Pharmacokinet. 17:1-9.
6. Conover, W. J. 1980. Some methods based on ranks, p. 213-343. In Practical non-parametric statistics, 2nd ed. John Wiley & Sons, Inc., New York, N.Y.
7. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
8. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41: 1099-1107.
9. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, et al. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
10. Harker, A. J., G. L. Evans, A. E. Hawley, and D. M. Morris. 1994. High-performance liquid chromatographic assay for 2′-deoxy-3′-thiacytidine in human serum. J. Chromatogr. B Biomed. Appl. 657:227-232.
11. Horton, C. M., G. Yuen, D. M. Mikolich, A. Fisher, K. Rana, P. Mydlow, and M. N. Dudley. 1994. Pharmacokinetics (PK) of oral lamivudine administered alone and with oral zidovudine (ZDV) in asymptomatic patients with human immunodeficiency virus (HIV) infection. Clin. Pharmacol. Ther. 55:198 (abstr. PIII-64).
12. Hughes, W., J. A. McDowell, J. Shenep, P. Flynn, M. W. Kline, R. Yogev, W. Symonds, Y. Lou, and S. Hetherington. 1999. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob. Agents Chemother. 43:609-615.
13. Kewn, S., G. J. Veal, P. G. Hoggard, M. G. Barry, and D. J. Back. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:589-595.
14. Kost, R., Y. Cao, M. Vesanen, A. Talal, A. Hurley, R. Schluger, S. Monard, M. Rogers, J. Johnson, L. Smiley, D. Ho, and M. Markowitz. 1998. Combination therapy with abacavir (1592), 141W94, and AZT/3TC in subjects acutely and chronically infected with HIV, abstr. 363, p. 147. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
15. Kumar, P. N., D. E. Sweet, J. A. McDowell, W. Symonds, Y. Lou, S. Hetherington, and S. LaFon. 1999. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type-1 infected adults. Antimicrob. Agents Chemother. 43:603-608.
16. Mellors, J. W., K. Hertogs, F. Peeters, R. Lanier, V. Miller, N. Graham, B. Larder, P. Stoffels, and R. Pauwels. 1998. Susceptibility of clinical HIV-1 isolates to 1592U89, abstr. 687, p. 208. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
17. Morse, G. D., M. J. Shelton, M. Ho, L. Bartos, M. DeRemer, and M. Ragni. 1995. Pharmacokinetics of zidovudine and didanosine during combination therapy. Antivir. Res. 27:419-424.
18. Prins, J., S. Jurriaans, M. Roos, F. De Wolf, F. Miedema, and J. Lange. 1998. An attempt at maximally suppressive anti-HIV therapy, abstr. 385, p. 150. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
19. Rana, K. Z., C. M. Horton, G. J. Yuen, P. E. Pivarnik, D. M. Mikolich, A. E. Fisher, P. K. Mydlow, and M. N. Dudley. 1994. Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-infected individuals, abstr. A62, p. 83. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Ravitch, J. R., B. J. Bryant, M. J. Reese, C. C. Boehlert, J. S. Walsh, J. P. McDowell, and B. M. Sadler. 1998. In vivo and in vitro studies of the potential for drug interactions involving the anti-retroviral 1592 in humans, abstr. 634, p. 199. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
21. Saag, M. S., A. Sonnerborg, R. A. Torres, D. Lancaster, B. G. Gazzard, R. T. Schooley, C. Romero, D. Kelleher, W. Spreen, S. LaFon, and the Abacavir Phase 2 Clinical Team. Antiretroviral effect and safety of abacavir and abacavir in combination with zidovudine in HIV-infected adults. AIDS 12: F203-F209.
22. Shelton, M. J., A. Portmore, M. R. Blum, B. M. Sadler, R. C. Reichman, and G. D. Morse. 1994. Prolonged but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy 14:671-677.
23. Staszewski, S., C. Katlama, T. Harrer, P. Massip, P. Yeni, A. Cutrell, S. M. Tortell, P. R. Harrigan, H. Steel, E. R. Lanier, and G. Pearce. A dose-ranging study to evaluate the safety and efficacy of three doses of abacavir (1592U89) alone or in combination with zidovudine and lamivudine in antiretroviral treatment naive subjects. AIDS 12:F197-F202.
24. Staszewski, S., C. Katlama, T. Harrer, P. Massip, P. Yeni, A. Cutrell, S. M. Tortell, H. M. Steel, E. R. Lanier, and G. Pearce. 1998. Preliminary long-term open-label data from patients using abacavir (1592) containing antiretroviral treatment regimens, abstr. 658, p. 203. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
25. St. Clair, M. H., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. M. Sadler, M. R. Blum, and G. Painter. 1996. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antivir. Res. 29: 53-56.
26. Symonds, W. T., J. McDowell, G. Chittick, J. Moss, and A. Bye. 1996. The safety and pharmacokinetics of GW1592U89, zidovudine, and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients. AIDS 10(Suppl. 2):S23.
27. Tadepalli, S. M., L. Puckett, S. Jeal, L. Kanics, and R. P. Quinn. 1990. Differential assay of zidovudine and its glucuronide metabolite in serum and urine with a radioimmunoassay kit. Clin. Chem. 36:897-900.
28. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
29. Torres, R., M. Saag, D. Lancaster, A. Sonnerborg, J. Feinberg, M. Thompson, W. Lang, R. Schooley, J. Mulder, R. D'Aquila, M. Santin, and S. Lafon. 1998. Antiviral effects of abacavir (1592) following 36 weeks of therapy, abstr. 659, p. 203. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
30. Unadkat, J. D., A. C. Collier, S. S. Crosby, D. Cummings, K. E. Opheim, and L. Corey. 1990. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 4:229-232.